

























































published: 15 August 2014
doi: 10.3389/fonc.2014.00220
Microparticles mediate the intercellular regulation of
microRNA-503 and proline-rich tyrosine kinase 2 to alter
the migration and invasion capacity of breast cancer cells
Joyce Gong1,2, Frederick Luk 1, Ritu Jaiswal 1 and Mary Bebawy 1*
1 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia





Sophia Ran, Southern Illinois
University, USA
A. Emre Sayan, University of
Southampton, UK
*Correspondence:
Mary Bebawy, Discipline of
Pharmacy, Graduate School of Health,
Level 13, Building 1, University of
Technology Sydney, PO Box 123,
Broadway, NSW 2007, Australia
e-mail: Mary.Bebawy@uts.edu.au
The successful treatment of cancer is hampered by drug resistance and metastasis.
While these two obstacles were once considered separately, recent evidence associates
resistance with an enhanced metastatic capacity. However, the underlying mechanisms
remain undefined. We previously described the intercellular transfer of drug resistance
via submicron vesicles called microparticles (MPs). We now propose that MPs derived
from drug-resistant cells are also involved in the intercellular transfer of components to
enhance the migration and invasion capacity of cells.Thus, MPs may be a conduit between
resistance and metastasis. We used microarray analysis to identify regulatory microRNAs
(miRNAs), which contribute to the dissemination of metastatic traits. miR-503 was down-
regulated in recipient cells following co-culture with MPs isolated from drug-resistant cells.
miR-503 was inversely associated with metastasis, as demonstrated using wound heal-
ing/scratch migration assays and Matrigel®-coated transwell invasion assays. Proline-rich
tyrosine kinase 2 (PYK2) was upregulated in recipient cells and associated with increased
migration and invasion, with these phenotypes being reversed using a pharmacological
inhibitor of PYK2 phosphorylation, tyrphostin A9. However, the MP-mediated promotion of
metastatic traits was not due to the presence of these effectors in the MP cargo but rather
due to down stream effector molecules in these pathways. This is the first demonstration
that the role of MPs in trait acquisition extends beyond the direct transfer of vesicle com-
ponents and also includes transfer of intermediary regulators that induce down stream
mediators following transfer to recipient cells. This implicates an expanding role of MPs in
cancer pathogenesis.
Keywords: breast cancer, metastasis, microparticles, microarray, microRNA, microRNA-503, multidrug resistance,
proline-rich tyrosine kinase 2
INTRODUCTION
The development of drug resistance and metastases are signifi-
cant hindrances to the successful treatment of cancer. Of clinical
significance is multidrug resistance (MDR) associated with the
overexpression of efflux transporters such as P-glycoprotein (P-
gp). P-gp recognizes numerous drug substrates and expels them
from cells, maintaining a sublethal intracellular concentration,
resulting in treatment failure (1). Recently, P-gp-mediated MDR
and the emergence of an enhanced metastatic capacity have been
linked in laryngeal carcinoma (2) and breast cancer (3, 4). These
studies show that the overexpression of P-gp may be predictive of
increased migration and invasive capacity.
We have shown that small plasma membrane-derived vesi-
cles called microparticles (MPs) are involved in the dissemination
of MDR (5–8). MPs are vesicles 0.1–1µm in diameter that are
released from cells by membrane budding (9, 10). As such, MPs
Abbreviations: MDR, multidrug resistance; miRNA, microRNA; MPs, microparti-
cles; P-gp, P-glycoprotein; PYK2, proline-rich tyrosine kinase 2.
carry surface antigens, proteins, cytoplasmic and nuclear con-
stituents from the donor cell (5–7, 11, 12). MPs differ from other
submicron vesicles such as exosomes in terms of size, shape, con-
tent, and origin. Exosomes are smaller (40–80 nm in diameter)
and are carried within multivesicular bodies, which fuse with the
plasma membrane and release their content (13).
We have shown that MPs can transfer regulatory microRNAs
(miRNAs) from donor drug-resistant cancer cells to recipient
drug-sensitive cancer cells, effectively re-templating recipient cells
to reflect donor cell traits (6–8). miRNAs are small non-coding
nucleic acids, 19–25 nucleotides in length, capable of regulating
transcriptional and post-transcriptional gene expression by pair-
ing with the 3′-untranslated region (UTR) of target mRNAs (14).
Herein, we examined the involvement of MPs derived from drug-
resistant breast cancer cells in conferring an enhanced migration
and invasion capacity to recipient cells. In particular, we found a
MP-mediated involvement of miR-503 and proline-rich tyrosine
kinase 2 (PYK2).
The regulation of miR-503 has been previously shown to be
involved in the development of drug resistance and metastatic
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traits, with reduced levels of miR-503 being identified in drug-
resistant cells (15) and highly metastatic cells (16). One pathway
by whichmiR-503 acts as a tumor suppressor is via downregulation
of phosphatidylinositol 3-kinase (PI3K)/AKT signaling (17). The
PI3K/AKT signaling pathway plays an important role in the pro-
gression of breast cancer (18, 19). As a major pathway, PI3K/AKT
signaling is not only regulated bymiR-503 but also by other factors
including the focal adhesion kinase PYK2. PYK2, also known as
related adhesion focal tyrosine kinase (RAFTK) or protein tyro-
sine kinase 2 beta (PTK2B), is a member of the focal adhesion
kinase subfamily of cytoplasmic tyrosine kinases (20). Elevated
levels of PYK2 have been associated with enhanced migration and
invasion via activation of the PI3K/AKT signaling pathway (21).
Here, we have investigated the role of MPs derived from drug-
resistant cells in not only disseminating the drug resistance trait
but also in the regulation of both miR-503 and PYK2 in recipi-
ent cells to promote migration and invasion. Therefore, MPs may
provide a conduit between drug resistance and an enhanced migra-




The drug-sensitive human breast adenocarcinoma cell line MCF-7
and its drug-resistant subline MCF-7/Dx were cultured as pre-
viously described (6, 7). The drug-sensitive human acute lym-
phoblastic leukemia cell line CCRF-CEM (designated CEM for
simplicity) and its drug-resistant variant VLB100 were also used
as previously described (6, 7). All cells were cultured with RPMI
1640 culture medium supplemented with 10% fetal bovine serum
(FBS) at 37°C with 5% CO2.
MICROPARTICLE ISOLATION
Microparticles were isolated as previously described (22). Briefly,
cell culture supernatants were centrifuged at 500× g for 5 min to
pellet cells and large debris. The supernatant was centrifuged again
at 15,000× g for 1 h at 17°C to pellet MPs. The MP pellet was resus-
pended in serum-free media and centrifuged at 2,000× g for 1 min
to remove small debris and the remaining supernatant centrifuged
again at 18,000× g for 30 min at 17°C to pellet MPs. The iso-
lated MP fraction was validated by flow cytometric analysis (LSRII
flow cytometer, BD Biosciences, Sydney, NSW,Australia) following
V450 Annexin V labeling (BD Biosciences) and by size as previ-
ously described (5). The total protein content of the MP fraction
was determined using the Qubit® protein assay (Life Technologies,
Melbourne, VIC, Australia) following the manufacturer’s recom-
mendation. MPs isolated from MCF-7 and MCF-7/Dx cells were
designated MCFMPs and DxMPs, respectively. MPs isolated from
CEM and VLB100 cells were designated CEMMPs and VLBMPs,
respectively.
CO-CULTURE CONDITIONS
1× 105 drug-sensitive MCF-7 cells were co-cultured with 100µg
MCFMPs or DxMPs in culture medium for 4 h. Cells were cen-
trifuged at 500× g for 5 min and washed twice with phosphate-
buffered saline (PBS) to remove MPs. Cells were then analyzed as
outlined below.
MIGRATION AND INVASION ASSAYS
In assessing cell migration, a wound healing/scratch migration
assay was used. Confluent cells grown in six-well culture plates
(Corning, Sydney, NSW, Australia) were scratched using a sterile
10µL pipette tip and washed twice to remove detached cells and
debris. Cell migration was monitored at 0 and 48 h post-scratch.
The closure of the wound after 48 h was measured using ImageJ
software and the percentage wound closure relative to that mea-
sured at 0 h was calculated. As both MCF-7 and MCF-7/Dx cell
lines have a doubling time of 24 h (data not shown), the extent of
wound closure is reflective of the migration capacity of cells rather
than the result of difference in doubling time.
The invasive capacity of cells was determined using transwell
inserts (24-well 6.5 mm insert, pore size 8µm, Corning). Inserts
were coated with Matrigel® basement membrane (BD Biosciences)
before cells were seeded to the upper chamber in serum-free RPMI
1640. RPMI 1640 with 10% FBS was added to the lower chamber as
a chemoattractant. After incubation for 48 h at 37°C and 5% CO2,
the cells that had emerged from the underside of the Matrigel®-
coated inserts were fixed and stained with 0.5% crystal violet in
20% methanol for 10 min.
IDENTIFICATION OF microRNAs ASSOCIATED WITH THE ACQUISITION
OF DRUG RESISTANCE
Total RNA was pooled from duplicate experiments and extracted
using the Tri Reagent method (Molecular Research Center, Cincin-
nati, OH, USA). RNA integrity was determined using the Agilent
RNA 6000 Nano kit and Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Melbourne, VIC, Australia). Total RNA was quantitated
by Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific,
Melbourne, VIC, Australia). miRNA microarray analysis was per-
formed with internal replicates for each probe on the Affymetrix
GeneChip® miRNA Array (Affymetrix, Santa Clara, CA, USA) by
the Australian Genome Research Facility Ltd. (Melbourne, VIC,
Australia) as previously described by us (7). Microarray data can be
accessed in NCBI’s Gene Expression Omnibus through GEO Series
accession number GSE34560 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE34560). Data were processed to include
only human miRNAs with p-values< 0.06. We compared the
miRNA expression profiles from samples derived from: (A) drug-
resistant cells (MCF-7/Dx or VLB100), and (B) drug-sensitive cells
co-cultured with MPs derived from drug-resistant cells (MCF-
7+DxMPs or CEM+VLBMPs) with (C) drug-sensitive cells
(MCF-7 or CEM). miRNAs with a fold change greater than 1.5
were identified and used for subsequent analysis. The profile
of differentially expressed miRNAs as determined by compari-
son analysis was represented as a Venn diagram with the final
list of miRNAs representative of miRNAs that were differentially
expressed in drug-resistant cells and co-cultured cells relative to
drug-sensitive cells.
TRANSFECTION OF miR-503 antagomiR AND pre-miR
We sought to determine the functional consequences of MP-
transferred miR-503 on recipient cells. mirVana® miR-503
antagomiR,mirVana®miR-503 pre-miR,and its scrambled control
(Life Technologies) were used to study the effect of miR-503 on the
migration and invasion capacity of cells. MCF-7 and MCF-7/Dx
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cells were transfected for 24 h with 40 nM miR-503 antagomiR,
pre-miR or the scrambled control using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s instructions. MCF-
7 and MCF-7/Dx cells were assessed for their migration and
invasion capacity using migration and invasion assays as described
above.
PROLINE-RICH TYROSINE KINASE 2 EXPRESSION
Proline-rich tyrosine kinase 2 is also associated with the promo-
tion of migration and invasion. To determine the expression levels
of PYK2 in MCF-7 cells, MCF-7 cells co-cultured with DxMPs,
MCF-7/Dx cells, and DxMPs, samples were lysed using CelLytic™
M Cell Lysis reagent (Sigma-Aldrich, Sydney, NSW,Australia) with
1% (v/v) protease inhibitor cocktail (Sigma-Aldrich) according to
the manufacturer’s recommendation. The lysates were centrifuged
at 10,000× g for 10 min at 4°C and protein content quantified by
Qubit® protein assay (Life Technologies). Total protein was sep-
arated by electrophoresis using a 4–12% NuPAGE™ Bis-Tris gel
(Life Technologies) and PYK2 was detected by Western blot using
anti-PYK2 (clone 5E2) mouse monoclonal antibody. Anti-β-actin
(clone AC-74) antibody was used as an internal loading control.
The presence of the Pyk2 gene transcript was assessed by
quantitative real time PCR (qRT-PCR). Briefly, total RNA was
extracted from samples by the Tri Reagent method (Molecu-
lar Research Center) according to the manufacturer’s instruc-
tions. cDNA was synthesized using the Advantage RT-for-
PCR Kit (Clontech Laboratories, Mountain View, CA, USA)
on the Eppendorf MasterCycler Gradient (Eppendorf, Haup-
pauge, NY, USA). The following primers (Sigma-Aldrich)
were used: Pyk2 forward: 5′-CCCAGCCGACCTAAGTACAG-
3′; reverse: 5′-CACACAGACCCTCAGGAACC-3′. The follow-
ing housekeeping primers (Sigma-Aldrich) were used: GAPDH
forward: 5′-TGCCAAATATGATGACATCAAGAA-3′; reverse: 5′-
GGAGTGGGTGTCGCTGTTG-3′. SYBR Green (Takara Bio Inc.,
Mountain View, CA, USA) qRT-PCR amplifications were per-
formed on the Eppendorf Realplex 2 MasterCycler ep gradient
S (Eppendorf). The Ct data of each sample were collected auto-
matically. The ∆Ct of each group was calculated using the fol-
lowing formula:∆Ct= Pyk2 Ct - GAPDH Ct. The relative expres-
sion levels were calculated using ∆∆Ct= 2−∆Ct and expressed
as fold differences from drug-sensitive MCF-7 cells: ([∆∆Ct of
sample÷∆∆Ct of MCF-7 cells]× 1).
STATISTICAL ANALYSIS
Data were analyzed using one-way analysis of variance (ANOVA)
with a post hoc Tukey’s multiple comparison test using the Graph
Pad Prism software. p-values< 0.05 were accepted as statistically
significant.
RESULTS
MICROPARTICLES ISOLATED FROMMDR CELLS ENHANCE THE
MIGRATION AND INVASION CAPACITY OF RECIPIENT CELLS
To determine the role of MPs in the regulation of migration and
invasion, we co-cultured drug-sensitive MCF-7 breast cancer cells
with MPs isolated from drug-resistant MCF-7/Dx cells (DxMPs)
and assessed their effects on cell migration and invasive capacity.
A wound was created in confluent layers of MCF-7, MCF-7/Dx,
and co-cultured cells (MCF-7+DxMPs). Closure of the wound
was imaged at the time the wound was created (0 h) and after 48 h
(Figure 1A). ImageJ analysis of the size of the wound allowed
for calculation of the percentage of wound closure after 48 h
(Figure 1B). On average, the size of the wound in MCF-7 cells
closed by 14%, indicating a low migratory capacity for this cell
line. In MCF-7/Dx cells, the wound closed completely after 48 h.
When co-cultured with DxMPs, the wound in the resultant popu-
lation closed by 45% during the same timeframe, indicating that
DxMPs increased the migratory capacity of MCF-7 cells, which
was reflective of that observed with the donor MCF-7/Dx cells.
In addition, MPs enhanced the invasive capacity of recipient
cells. The invasion of cells through a Matrigel® layer to the under-
side of a transwell membrane insert were observed (Figure 1C).
MCF-7 cells had a low invasive capacity, as evidenced by the low
number of cells that invaded the Matrigel® layer. In contrast, MCF-
7/Dx cells readily invaded to almost completely cover the underside
of the transwell. Consistent with that observed in the migration
assay, following MP co-culture of MCF-7 cells, an intermediate
number of co-cultured cells invaded the Matrigel® layer. There-
fore, DxMPs increased both the migratory and invasive capacity
of MCF-7 cells to reflect that observed for donor MCF-7/Dx cells.
IDENTIFICATION OF microRNAs ASSOCIATED WITH THE ACQUISITION
OF DRUG RESISTANCE
After identifying miRNAs that were packaged in MPs and deliv-
ered to recipient cells (7), we employed different selection criteria
to the microarray data to identify miRNAs associated with the
acquisition of drug resistance in recipient cells. Specifically, we
compared the differentially expressed miRNAs in co-cultured cells
to those in drug-resistant donor cells. Venn diagrams show that 63
(leukemia) and 117 (breast cancer) miRNAs were differentially
expressed in drug-resistant cells compared to drug-sensitive cells,
with 18 of these miRNAs being common to both cancer cell types
(Figure 2A). Similarly, 62 (leukemia) and 127 (breast cancer) miR-
NAs were differentially expressed in co-cultured cells compared to
drug-sensitive cells, with 19 of these miRNAs being common to
both cancer cell types. As a result, five miRNAs were identified
as being potentially associated with the MP-mediated acquisi-
tion of MDR: miR-22-3p, miR-185-5p, miR-503-5p, miR-652-3p,
and miR-1280. Of these, miR-503-5p (also known as miR-503)
was selected by us for further investigation due to its previous
association in suppressing the metastatic function of cells (16).
Microarray analysis showed that miR-503 expression was highest
in MCF-7 cells, with low levels in MCF-7/Dx cells, DxMPs, and
MCF-7 cells co-cultured with DxMPs (Figure 2B). Therefore, we
sought to transfect cells with a miR-503 antagomiR or miR-503
pre-miR to validate the effects of miR-503 on the migration and
invasion capacity of recipient cells.
PERTURBATION OF miR-503 ALTERED THE MIGRATION AND INVASIVE
CAPACITY OF BREAST CANCER CELLS
Closure of the wound created in confluent layers of MCF-7 and
MCF-7/Dx cells previously transfected with amiR-503 antagomiR,
pre-miR, or the scrambled control was assessed (Figure 3A).
The percentage wound closure after 48 h was then calculated
(Figure 3B). On average, the size of the wound in MCF-7 cells
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FIGURE 1 | Microparticles mediate the promotion of migration and
invasion in breast cancer. (A) Migratory capacity of breast cancer cells.
Wound healing/scratch migration assays of MCF-7 cells, MCF-7/Dx cells, and
MCF-7 cells co-cultured with DxMPs demonstrate the migratory capacity of
each cell type. Closure of the wound was assessed after 48 h. Data was
representative of at least three independent experiments. (B) Histograms
showing the percentage wound closure in breast cancer cells. Percentage
wound closure observed in ( ): MCF-7 cells, ( ): MCF-7/Dx cells, and ( ):
MCF-7 cells co-cultured with DxMPs. Data represent the mean±SEM of at
least three independent experiments. *p< 0.05. (C) Invasive capacity of
breast cancer cells. Transwell insert invasion by MCF-7 cells, MCF-7/Dx cells,
and MCF-7 cells co-cultured with DxMPs. Invasion of cells through a
Matrigel® layer to the underside of transwell membranes was assessed after
48 h. Data was representative of at least three independent experiments.
transfected with the scrambled control closed by 12%. In con-
trast,MCF-7 cells transfected with themiR-503 antagomiR showed
an increased percentage wound closure at 47%. When trans-
fected with the miR-503 pre-miR, the percentage wound closure
remained at similar levels to that observed following transfection
with the scrambled control at 14%. Drug-resistant MCF-7/Dx cells
transfected with the scrambled control had wounds that closed by
73%. Their transfection with the miR-503 antagomiR resulted in
complete closure of the wound while transfection with the miR-
503 pre-miR reduced the wound closure to 48%. The inhibition
of miR-503 thus resulted in increased migration of MCF-7 and
MCF-7/Dx cells, while mimicry of miR-503 reduced migration.
Moreover, miR-503 was involved in the invasive capacity of
MCF-7 and MCF-7/Dx cells. When MCF-7 cells were transfected
with the scrambled control, 12 cells per field of vision were present
on the underside of the transwell membrane (Figure 4). This
is consistent with MCF-7 cells having a low invasive capacity.
However, once MCF-7 cells were transfected with the miR-503
antagomiR, 107 cells per field of vision invaded the Matrigel® layer,
emerging on the underside of the transwell membrane. The num-
ber of invasive cells decreased to that observed with the scrambled
control when MCF-7 cells were transfected with the miR-503 pre-
miR. As observed in the migration assay, MCF-7/Dx cells trans-
fected with the scrambled control invaded through to the under-
side of the membrane to completely cover it (Figure 4). Again,
transfection with the miR-503 antagomiR resulted in increased
invasion of MCF-7/Dx cells, while transfection with the miR-503
pre-miR reduced invasion. Overall, the inhibition of miR-503
resulted in increased invasion of MCF-7 and MCF-7/Dx cells,
while the mimicry of miR-503 reduced their invasion.
MICROPARTICLES ISOLATED FROMMDR CELLS MEDIATE PYK2
EXPRESSION IN RECIPIENT CELLS
In addition tomiR-503 expression, the tyrosine kinase PYK2 is also
implicated in promoting cancer metastasis. Western blot analysis
was used to detect the presence of PYK2 in MCF-7 cells, co-
cultured cells, MCF-7/Dx cells, and DxMPs. PYK2 was identified
at 116 kDa (Figure 5A). MCF-7 cells expressed low levels of PYK2
(lane 1). However, once they were co-cultured with DxMPs, there
was an increase in PYK2 expression (lanes 2, 3, and 4). Donor
MCF-7/Dx cells expressed the most PYK2 (lane 5). However, their
MPs expressed negligible levels of PYK2 (lane 7).
We next sought to determine the expression profile of the Pyk2
gene transcript using qRT-PCR. The level of Pyk2 in each sam-
ple was expressed as a fold difference relative to that present in
MCF-7 cells (Figure 5B). MCF-7/Dx cells expressed 3.8-fold less
Pyk2 than MCF-7 cells, with their MPs expressing 8.2-fold less.
Although DxMPs expressed very little of the transcript, once they
were co-cultured with MCF-7 cells, the resultant recipient cell pop-
ulation showed a dramatic 3.9-fold increase in Pyk2 expression.
A co-culture with MCFMPs (MPs derived from MCF-7 cells) was
used as a control, and resulted in an insignificant 1.27-fold increase
in Pyk2 expression. Therefore, the increased Pyk2 expression in
co-cultured cells was not due to a membrane-induced artifact
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FIGURE 2 | Microarray analysis of expressed miRNAs. (A) Profile of
differentially expressed miRNAs as determined by comparison analysis. Venn
diagrams illustrate miRNAs that were differentially expressed in drug-resistant
cells compared to drug-sensitive cells and miRNAs that were differentially
expressed in co-cultured cells compared to drug-sensitive cells. Five miRNAs
were common across both cancers that were differentially expressed in
drug-resistant and co-cultured cells compared to drug-sensitive cells.
(B) Expression of miR-503 as determined by microarray analysis. Microarray
expression levels of miR-503 in ( ): MCF-7 cells, ( ): MCF-7/Dx cells, ( ):
DxMPs, and ( ): MCF-7 cells co-cultured with DxMPs.
following exposure to MPs, but rather to an interaction specific
to DxMPs, independent of their own Pyk2 expression levels.
INCREASED PYK2 EXPRESSION PROMOTES MIGRATION AND
INVASION
In order to determine the functional effect of PYK2 on migra-
tion and invasion, wound healing/scratch migration and transwell
invasion assays were again conducted. Cells were treated with
10µM of the PYK2 phosphorylation inhibitor tyrphostin A9 to
determine whether functional PYK2 had effects on migration and
invasion. The closure of the wound created in confluent layers
of MCF-7 cells, MCF-7/Dx cells, and MCF-7 cells co-cultured
with DxMPs was assessed following treatment with tyrphostin
A9 or with the solvent control (Figure 6A). Closure of the wound
was imaged after 48 h. ImageJ analysis of the size of the wound
allowed for calculation of the percentage of wound closure after
48 h (Figure 6B). On average, the wound in MCF-7 cells with-
out tyrphostin A9 treatment closed by 10%. This decreased to 5%
when MCF-7 cells were treated with tyrphostin A9. As expected,
MCF-7/Dx cells without tyrphostin A9 showed complete closure
of the wound. However, once they were treated with tyrphostin
A9, this decreased to 60%. When MCF-7 cells were co-cultured
with DxMPs, the migratory capacity increased to reflect that of the
donor cell, with the wound in co-cultured cells without tyrphostin
A9 closing by 58%. Again, treatment with tyrphostin A9 reduced
the percentage wound closure to 34%. Therefore, inhibition of the
phosphorylation of PYK2 resulted in decreased migration.
Consistent with the results in the migration assay, the tran-
swell invasion assay demonstrated that treatment with tyrphostin
A9 reduced the invasion of cells through a Matrigel® layer. With
and without tyrphostin A9 treatment, MCF-7 cells were trapped
within the Matrigel® layer and did not invade on the under-
side of the transwells (Figure 6C). In contrast, while MCF-7/Dx
cells strongly invaded the Matrigel® layer, when treated with tyr-
phostin A9, fewer cells penetrated to the underside of the tran-
swell membrane. Similar to the migration assay, MCF-7 cells
co-cultured with DxMPs displayed an intermediate invasive capac-
ity relative to recipient MCF-7 cells and donor MCF-7/Dx cells,
with several cells invading the Matrigel® layer. As with MCF-
7/Dx cells, treatment with tyrphostin A9 reduced the ability of
co-cultured cells to invade. Therefore, inhibition of PYK2 phos-
phorylation using tyrphostin A9 reduced the invasive capacity
of cells.
miR-494 AND miR-330-3p REGULATE Pyk2 EXPRESSION
Microarray analysis of MCF-7 cells, MCF-7/Dx cells, and MCF-7
cells co-cultured with DxMPs showed that miR-494 was highly
expressed in co-cultured cells compared to the parental cells
(Figure 7A). Conversely, miR-330-3p was expressed in low lev-
els in co-cultured cells (Figure 7B). Using the online database
miRDB for miRNA target prediction and functional annotations
(http://mirdb.org/miRDB), we identified Pyk2 as a target of these
miRNAs. Therefore, they may be a means by which MPs promote
the expression of Pyk2.
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FIGURE 3 |miR-503 is involved in regulating the migratory capacity of
breast cancer cells. (A) Migratory capacity of transfected breast cancer cells.
Wound healing/scratch migration assays of MCF-7 cells and MCF-7/Dx cells
demonstrate the migratory capacity of each cell type and the effect of the
inhibition or mimicry of miR-503 on this capacity. Closure of the wound was
assessed after 48 h. Data was representative of at least three independent
experiments. (B) Histograms showing percentage wound closure in
transfected breast cancer cells. Percentage wound closure observed in ( ):
MCF-7 cells transfected with the scrambled control, ( ): MCF-7 cells
transfected with the miR-503 antagomiR, ( ): MCF-7 cells transfected with
the miR-503 pre-miR, ( ): MCF-7/Dx cells transfected with the scrambled
control, ( ): MCF-7/Dx cells transfected with the miR-503 antagomiR, and
( ): MCF-7/Dx cells transfected with the miR-503 pre-miR. Data represent
the mean±SEM of at least three independent experiments. *p<0.05.
DISCUSSION
Although the development of drug resistance and metastases are
both major considerations in the clinical treatment of cancer, they
have only recently been studied together. The drug-resistant MCF-
7/Dx cells used in this study are cells that have been derived from
drug-sensitive MCF-7 cells by incremental exposure to doxoru-
bicin (23). In transforming these cells to a drug-resistant phe-
notype, MCF-7/Dx cells have also gained characteristics that are
reflective of a mesenchymal phenotype (24, 25). Compared to
MCF-7 cells, MCF-7/Dx cells grow in a disperse manner rather
than in clusters, have lost the expression of E-cadherin while gain-
ing expression of N-cadherin, which is a hallmark of epithelial to
mesenchymal transition (EMT) (24), are vimentin-positive, and
are highly invasive (25).
We have shown that MPs disseminate drug resistance (5–7,
12). Here, we have elucidated the larger role of MPs derived
from drug-resistant breast cancer cells in disseminating compo-
nents to promote the migration and invasion capacity of recipient
cells. This is the first demonstration that MPs derived from drug-
resistant cells also confer an enhanced migration and invasion
capacity. Therefore, MPs may serve as a conduit between drug
resistance and migration and invasion. To identify the possible
mechanisms behind this relationship, we studied the differential
expression of miRNAs in our breast cancer model and the role of
MPs in their distribution between cells.
Selection criteria identified miRNAs that were acquired by
co-cultured recipient cells identical to those present in donor drug-
resistant cells. This approach aided in identifying five miRNAs that
were associated with the dissemination of MDR by MPs. Of the
five miRNAs, miR-503 was further explored as it has been previ-
ously implicated in drug resistance and migration and invasion
capacity in cancer (15, 16).
In this study,we describe a role for MPs in the regulation ofmiR-
503 and transfer of an enhanced migration and invasion capacity
from drug-resistant to drug-sensitive cells. We observed an inverse
relationship between miR-503 and migration and invasion capac-
ity. Specifically, we observed high miR-503 levels in drug-sensitive
MCF-7 cells, which have a low migration and invasion capacity. In
contrast, lower levels of miR-503 were observed in drug-resistant
MCF-7/Dx cells, which have a higher migration and invasion
capacity. Transfection with a miR-503 antagomiR increased the
migration and invasion of both cells (Figures 3 and 4). In contrast,
transfection with a miR-503 pre-miR reduced migration and inva-
sion (Figures 3 and 4). Moreover, upon co-culture with DxMPs,
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FIGURE 4 |miR-503 is involved in regulating breast cancer invasive
capacity. Transwell insert invasion by MCF-7 cells and MCF-7/Dx cells
demonstrate the invasive capacity of each cell type and the effect of the
inhibition or mimicry of miR-503 on this capacity. Invasion of cells through a
Matrigel® layer to the underside of transwell membranes was assessed after
48 h. Data was representative of at least three independent experiments.
recipient MCF-7 cells expressed low levels of miR-503 and had
a greater migration and invasion capacity, similar to donor cells.
Therefore, both the inhibition of miR-503 by transfection and fol-
lowing co-culture with DxMPs, reduced the levels of miR-503 in
recipient cells and increased their migration and invasion capacity.
Therefore, it is highly likely that DxMPs carry and transfer inter-
mediates that result in the inhibition of miR-503 in recipient cells,
promoting migration and invasion.
Activation of the NF-κB pathway has been shown to suppress
the expression of miR-503 in epithelial cells (26). Furthermore,
NF-κB signaling is a significant aspect of the development of drug
resistance in cancer, such that drugs that inhibit the NF-κB path-
way result in reversal of the MDR phenotype (27–29). Moreover,
NF-κB has been associated with the promotion of migration and
invasion in breast cancer (30). Therefore, it is feasible that MPs
enable the activation of NF-κB signaling and its subsequent sup-
pression of miR-503 to facilitate both the development of drug
resistance and the enhancement of metastatic traits.
Reduced levels of miR-503 were observed in cisplatin-resistant
non-small cell lung cancer (NSCLC) cells, while its overexpres-
sion re-sensitized these cells to cisplatin via modulation of the
apoptosis regulator Bcl-2 (15). Furthermore,miR-503 directly tar-
geted and repressed the Fanconi anemia complementation group
A protein (FANCA) gene to sensitize NSCLC cells to cisplatin treat-
ment (31). In addition to its role in drug resistance, miR-503 also
serves as a tumor suppressor. Overexpression of miR-503 inhibited
the migration and invasion of the highly invasive hepatocellular
carcinoma (HCC) cell line, HCCLM3 (16), induced G1 cell cycle
arrest and reduced the proliferation of HCCLM3 cells (16, 32), an
acute myeloid leukemia cell line (33), human glioblastoma multi-
forme (GBM) cell lines (17), osteosarcoma cells and colon cancer
cells (34), and suppressed the proto-oncogene cyclin D1 (CCND1)
in a human head and neck carcinoma cell line (35). Furthermore,
miR-503 was shown to initiate its tumor suppressive activity via
regulation of PI3K/AKT signaling by inhibiting AKT activation
(17) and suppressing the PI3K p85 subunit (36).
PI3K/AKT signaling is a major contributor to the aberrant
growth and rapid spread of cancer and therefore holds significant
interest in the field of cancer therapy (37, 38). Similar to its role
in suppressing miR-503, and thereby upregulating PI3K/AKT sig-
naling, MPs may further perpetuate this pathway by mediating the
expression of PYK2. High levels of PYK2 were associated with poor
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FIGURE 5 | Upregulation of PYK2 protein and transcript following
co-culture with DxMPs. (A) PYK2 protein expression as determined
by Western blotting. Total lysates of MCF-7 cells (lane 1), MCF-7 cells
co-cultured with DxMPs (lanes 2, 3, and 4), MCF-7/Dx cells (lane 5), and
DxMPs (lane 7) were examined for PYK2 expression by Western
blotting using the PYK2 (clone 5E2) mAb. β-actin was used as an
internal control. Data was representative of at least three independent
experiments. (B) Pyk2 gene transcript expression as determined by
qRT-PCR. Pyk2 gene transcript in ( ): MCF-7 cells, ( ): MCF-7/Dx cells,
( ): DxMPs, ( ): MCF-7 cells co-cultured with MCFMPs, and ( ):
MCF-7 cells co-cultured with DxMPs. Values are expressed as the fold
difference relative to MCF-7 cells using GAPDH as the endogenous
control. Data represent the mean±SEM of at least three independent
experiments. *p<0.05.
survival and metastasis in HCC via activation of the PI3K/AKT
pathway by PYK2-dependent phosphorylation of AKT, which was
reversed by the PI3K/AKT inhibitor LY294002 (21). PYK2 has been
further implicated in cancer cell migration and invasion (39), with
elevated levels of PYK2 correlating with the progression of HCC
(40, 41) and astrocytomas (42). Increased PYK2 expression was
observed in early and advanced breast cancer compared to benign
and normal breast tissue (39), and in pulmonary metastases, with
the inhibition of PYK2 resulting in reduced tumor development
and metastasis (20). Furthermore, the expression of PYK2 was
found to increase the invasive potential of MDA-MB-435 and
MCF-7 breast cancer cells via activation of Src and the MAP kinase
pathway (43). The overexpression of PYK2 also induced EMT in
Hep3B HCC cells, promoting cell motility and invasiveness for
enhanced metastasis (44). This may be due to the involvement of
PYK2 in upregulating the phosphorylation and localization of the
transcription factor Hic-5, which regulates EMT (44). Moreover,
these effects were downregulated upon suppression of PYK2 in
metastatic MHCC97L HCC cells (44).
In agreement with the above studies, we observed low PYK2
in lowly metastatic MCF-7 cells and high expression in highly
metastatic MCF-7/Dx cells. Once MCF-7 cells were co-cultured
with DxMPs, there was an increase in PYK2. However, there were
no detectable amounts of PYK2 in the DxMPs themselves. Simi-
larly, when we investigated expression of the Pyk2 gene transcript,
there were very low levels in both DxMPs and the donor MCF-7/Dx
cells. However, there was a 3.9-fold increase of Pyk2 in co-cultured
cells compared to MCF-7 cells (Figure 5). Given that DxMPs did
not carry either the protein or the gene transcript, there must be
other intermediates contained within the vesicle cargo by which
DxMPs upregulate PYK2 and Pyk2 expression independent of the
PYK2 load itself. Therefore, the acquisition of protein and tran-
script in recipient cells was independent of their presence in the MP
cargo. This expands our understanding of the intercellular trans-
fer of cellular constituents by microvesicles until now, the cellular
constituents acquired were present in the donor cells and/or their
MPs. This introduces for the first time a capacity to readily estab-
lish proteomic and transcriptional variants independent of that
which is directly contained within the MP cargo, possibly via the
transfer of intermediate regulators.
For instance, microarray analysis showed that miR-494 was
highly expressed in co-cultured cells compared to MCF-7 and
MCF-7/Dx cells (Figure 7A). miR-494 is predicted to target
the focal adhesion kinase family interacting protein of 200 kDa
(FIP200) gene. FIP200, also known as retinoblastoma coiled coil
protein 1 (RB1CC1), has been shown via co-transfection, bind-
ing, and co-immunoprecipitation assays to bind directly to the
kinase domain of PYK2 and inhibit its activity (45). Naturally,
the downregulation of FIP200 increased the activity of PYK2
(46). Therefore, the high level of miR-494 may be involved in
downregulating the FIP200 gene, enabling the overexpression
of Pyk2, and subsequent enhancement of metastatic traits in
co-cultured cells.
Concurrently, miR-330-3p was detected in low levels in
co-cultured cells compared to MCF-7 and MCF-7/Dx cells
(Figure 7B). Being a regulator of Pyk2, it correlated with
the overexpression of Pyk2 in co-cultured cells. Therefore, the
observed downregulation of miR-330-3p in co-cultured cells may
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FIGURE 6 | Inhibition of PYK2 phosphorylation is associated with
decreased migratory capacity. (A) Migratory capacity of breast cancer
cells. Wound healing/scratch migration assays of MCF-7 cells, MCF-7/Dx
cells, and co-cultured cells demonstrate the migration capacity of each
cell type and the effect of the PYK2 phosphorylation inhibitor tyrphostin
A9 on this capacity. Cells were incubated without or with tyrphostin A9
and closure of the wound was assessed after 48 h. Data was
representative of at least three independent experiments. (B) Histograms
showing the percentage wound closure in breast cancer cells. The
percentage wound closure observed in ( ): MCF-7 cells without
tyrphostin A9, ( ): MCF-7 cells with tyrphostin A9, ( ): MCF-7/Dx cells
without tyrphostin A9, ( ): MCF-7/Dx cells with tyrphostin A9, ( ): MCF-7
cells co-cultured with DxMPs without tyrphostin A9, and ( ): MCF-7 cells
co-cultured with DxMPs with tyrphostin A9. Data represent mean±SEM
of at least three independent experiments. *p<0.05. (C) Inhibition of
PYK2 phosphorylation is associated with decreased invasive capacity.
Transwell insert invasion by MCF-7 cells, MCF-7/Dx cells, and co-cultured
cells demonstrate the invasive capacity of each cell type and the effect of
tyrphostin A9 on this capacity. Cells were incubated without or with
tyrphostin A9 and the invasion of cells through a Matrigel® layer to the
underside of transwell membranes was assessed after 48 h. Data was
representative of at least three independent experiments.
also contribute to the PYK2-mediated promotion of migra-
tion and invasion. In this way, regulatory miRNAs may be a
means by which DxMPs alter PYK2 protein and gene transcript
expression in recipient cells independent of the protein or gene
transcript ultimately implicated downstream in the recipient
cells.
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FIGURE 7 | Expression of miRNAs as determined by microarray analysis. Expression levels of (A) miR-494 and (B) miR-330-3p in cells. Microarray
expression levels of miRNAs in ( ): MCF-7 cells, ( ): MCF-7/Dx cells, and ( ): MCF-7 cells co-cultured with DxMPs.
Another pathway by which DxMPs may upregulate PYK2 in
co-cultured cells is via expression of CD44. CD44 is a cell adhe-
sion molecule that has been shown to induce PYK2 phospho-
rylation via the activation of Src family kinases that phospho-
rylate PYK2, leading to its increased activity (47, 48). We have
recently shown that while CD44 is not expressed in parental
MCF-7 cells, it is present in donor MCF-7/Dx cells and their
MPs (12). However, upon co-culture with DxMPs, MCF-7 cells
did not acquire CD44 (12). Therefore, it is likely that DxMPs do
not directly transfer CD44 or PYK2, but rather that the inter-
action of CD44 found on DxMPs stimulates the activation of
PYK2 on recipient cells. Moreover, the upregulation of PYK2 only
occurred upon co-culture with DxMPs and not MCFMPs. This
lends further support to the link between MDR and the metasta-
tic trait, that only MPs derived from drug-resistant cells and not
MPs from drug-sensitive cells could increase the expression of
PYK2, resulting in the promotion of migration and invasion in
recipient cells.
CONCLUSION
MPs not only mediate the intercellular transfer of P-gp-mediated
MDR but are now also implicated in promoting migration and
invasion in recipient cells, potentially providing a link between
these two deleterious traits. Such mechanisms include the regula-
tion of miR-503 and PYK2 by MPs. Moreover, the modifications
observed in recipient cells were not due to the direct transfer of MP
cargo but rather through regulation by transferred intermediaries.
Therefore, the role of MPs in directly and indirectly mediating drug
resistance and metastasis pathways leading to the development
of a more aggressive phenotype warrants further investigation.
Addressing such a pathway has clinical implications as it has the
potential to improve the treatment of cancer.
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